CARsgen enrols first subject in trial of T-cell therapy for gastric cancer

CARsgen Therapeutics has enrolled the first subject in the confirmatory Phase II clinical trial of its autologous CAR T-cell therapy candidate, CT041, to treat CLDN18.2 positive advanced gastric/gastroesophageal junction cancer (GC/GEJ).

Free Whitepaper

Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States

Cell and gene therapies (CGT) have seen expansive clinical development and revenue growth over the past 5 years across various therapeutic areas. With the approval of 12 new therapies and the initiation of over 2,900 clinical trials between the analysis period of 2016 -2021, it is evident there is extensive investment in the innovation of CGT. Notably, oncology is the leading therapeutic area, with the highest percentage of new clinical development year-on year compared to other CGT therapy areas, indicating a high level of unmet needs and increased industry investment in the space. Access GlobalData’s new whitepaper, Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States to gain a better understanding of the developments, challenges and opportunities in CGT including exclusive insights on promising future oncology CGT assets in development. The white paper covers:

The key takeaways of cell and gene therapy
Extensive background on the uptake of cell and gene therapy
Insights and outlook of cell and gene therapy trials in the US
An analysis of the top oncology cell and gene therapy assets and developers

Enter your details here to receive the free whitepaper.

By GD50 Custom

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the GD50 Custom privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The first patient was enrolled at the Beijing Cancer Hospital in China.

GC/GEJ patients who have failed a minimum of two previous lines of treatments will be part of the trial.

An autologous CAR T-cell product against the protein Claudin18.2 (CLDN18.2), CT041 is being analysed to treat CLDN18.2 positive solid tumours with an initial focus on GC/GEJ and pancreatic cancer (PC).

The latest development comes after the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China granted approval to begin the trial in GC/GEJ patients.

The trial will analyse the safety and efficacy of CT041 to treat advanced GC/GEJ patients.

CT041 is claimed to be the only CLDN18.2-targeting CAR T-cell product candidate to enter a Phase II trial for solid tumour treatment.

It also showed favourable safety in ongoing trials.

The CAR T-cell therapy candidate obtained the US Food and Drug Administration’s (FDA) Orphan Drug designation and Orphan Medicinal Product designation from the European Medicines Agency to treat GC/GEJ and advanced GC in 2020 and 2021.

Apart from the confirmatory trial in China, CARsgen commenced a Phase Ib trial of the product to treat advanced GC/GEJ and PC in China and another Phase Ib trial for advanced gastric or pancreatic adenocarcinoma in North America.

The company plans to carry out a pivotal Phase II trial in North America this year.

CARsgen Therapeutics founder, board chairman, CEO and chief scientific officer Dr Zonghai Li said: “In the following clinical trials, we will further explore the efficacy and safety of CT041 in the treatment of advanced gastric/gastroesophageal junction cancer, as well as pancreatic cancer.

“We hope that CT041, a potential first-in-class CAR T-cell therapy, could make considerable progress and meet the unmet medical needs as soon as possible.”

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.